title: Twelve month clinical and angiographic outcome after stenting of unprotected left main coronary artery stenosis with paclitaxel-eluting stents--results of the multicentre FRIEND registry.
abstract: OBJECTIVE
  To evaluate the angiographic and clinical outcome of patients undergoing paclitaxel-eluting stent (PES) implantation for unprotected left main coronary artery (ULMCA) stenosis in a multicentre, prospective registry. The overall event rate for PCI of ULMCA disease remains higher than in on-label use making additional outcome data and risk-stratification tools for the ULMCA population desirable.
  
  
  RESULTS
  A prospective registry included all patients with a significant (> 50%) stenosis in ULMCA disease. In 151 of these patients the target lesion involved the distal bifurcation in 100 patients (66%), which was treated by predominantly using a "provisional T stenting" strategy. In distal ULMCA disease group, 72% had only one stent implantation while 28% had multiple (either 2 or 3) stents implanted. At a median follow-up of 472 +/- 75 days, cardiac death occurred in 3 patients (2%) and major adverse cardiac and cerebrovascular events (MACCE) in 16 patients (10.6%).
  
  
  CONCLUSIONS
  In the drug-eluting stent era, paclitaxel eluting stent implantation of ULMCA stenosis provided excellent immediate and mid-term results in this selected population, suggesting that it may be considered as a safe and effective alternative to CABG for selected patients with ULMCA who are treated in institutions performing large numbers of PCI procedures.
authors.affiliation: Cardiology Department, Rangueil Hospital, Toulouse, France. carrie.didier@chu-toulouse.fr
authors.forename: Didier
authors.initials: D
authors.lastname: Carrié
authors.forename: Hélène
authors.initials: H
authors.lastname: Eltchaninoff
authors.forename: Thierry
authors.initials: T
authors.lastname: Lefèvre
authors.forename: Marc
authors.initials: M
authors.lastname: Silvestri
authors.forename: Gilles
authors.initials: G
authors.lastname: Levy
authors.forename: Eric
authors.initials: E
authors.lastname: Maupas
authors.forename: Philippe
authors.initials: P
authors.lastname: Brunel
authors.forename: Jean
authors.initials: J
authors.lastname: Fajadet
authors.forename: Hervé
authors.initials: H
authors.lastname: Le Breton
authors.forename: Martine
authors.initials: M
authors.lastname: Gilard
authors.forename: Didier
authors.initials: D
authors.lastname: Blanchard
authors.forename: Bernard
authors.initials: B
authors.lastname: Glatt
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects / Q000295:instrumentation* / Q000401:mortality; D002317:Cardiovascular Agents / Q000008:administration & dosage*; D002318:Cardiovascular Diseases / Q000209:etiology / Q000401:mortality / Q000517:prevention & control*; D017023:Coronary Angiography; D023921:Coronary Stenosis / Q000000981:diagnostic imaging / Q000401:mortality / Q000628:therapy*; D054855:Drug-Eluting Stents; D005260:Female; D005602:France; D006801:Humans; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage*; D011446:Prospective Studies; D012042:Registries; D012720:Severity of Illness Index; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D002317:Cardiovascular Agents; D017239:Paclitaxel